118 related articles for article (PubMed ID: 29771500)
1. Rational Design of Cancer-Targeted Selenadiazole Derivative as Efficient Radiosensitizer for Precise Cancer Therapy.
Zeng D; Deng S; Sang C; Zhao J; Chen T
Bioconjug Chem; 2018 Jun; 29(6):2039-2049. PubMed ID: 29771500
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of cancer cells to radiation by selenadiazole derivatives by regulation of ROS-mediated DNA damage and ERK and AKT pathways.
Xie Q; Zhou Y; Lan G; Yang L; Zheng W; Liang Y; Chen T
Biochem Biophys Res Commun; 2014 Jun; 449(1):88-93. PubMed ID: 24813998
[TBL] [Abstract][Full Text] [Related]
3. Oridonin Enhances Radiation-Induced Cell Death by Promoting DNA Damage in Non-Small Cell Lung Cancer Cells.
Park H; Jeong YJ; Han NK; Kim JS; Lee HJ
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30104472
[TBL] [Abstract][Full Text] [Related]
4. Dual-function nanosystem for synergetic cancer chemo-/radiotherapy through ROS-mediated signaling pathways.
He L; Lai H; Chen T
Biomaterials; 2015 May; 51():30-42. PubMed ID: 25770995
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of RGD conjugated with Ketoprofen/Naproxen and radiolabeled with [
Mohammadi R; Shokri B; Shamshirian D; Zarghi A; Shahhosseini S
Daru; 2020 Jun; 28(1):87-96. PubMed ID: 31845157
[TBL] [Abstract][Full Text] [Related]
6. Rational Design of Cancer-Targeted Benzoselenadiazole by RGD Peptide Functionalization for Cancer Theranostics.
Yang L; Li W; Huang Y; Zhou Y; Chen T
Macromol Rapid Commun; 2015 Sep; 36(17):1559-65. PubMed ID: 26205253
[TBL] [Abstract][Full Text] [Related]
7. Selenadiazole derivatives as potent thioredoxin reductase inhibitors that enhance the radiosensitivity of cancer cells.
Liang YW; Zheng J; Li X; Zheng W; Chen T
Eur J Med Chem; 2014 Sep; 84():335-42. PubMed ID: 25036792
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Achilles' heel of cancer cells via integrin-mediated delivery of ROS-generating dihydrolipoamide dehydrogenase.
Dayan A; Fleminger G; Ashur-Fabian O
Oncogene; 2019 Jun; 38(25):5050-5061. PubMed ID: 30872792
[TBL] [Abstract][Full Text] [Related]
9. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
10. Highly stable selenadiazole derivatives induce bladder cancer cell apoptosis and inhibit cell migration and invasion through the activation of ROS-mediated signaling pathways.
Yang Y; Deng S; Zeng Q; Hu W; Chen T
Dalton Trans; 2016 Nov; 45(46):18465-18475. PubMed ID: 27711726
[TBL] [Abstract][Full Text] [Related]
11. Integrin α
Khatik R; Wang Z; Zhi D; Kiran S; Dwivedi P; Liang G; Qiu B; Yang Q
ACS Appl Mater Interfaces; 2020 Jan; 12(1):163-176. PubMed ID: 31805767
[TBL] [Abstract][Full Text] [Related]
12. Selenium promotes immunogenic radiotherapy against cervical cancer metastasis through evoking P53 activation.
Xu Y; Lai H; Pan S; Pan L; Liu T; Yang Z; Chen T; Zhu X
Biomaterials; 2024 Mar; 305():122452. PubMed ID: 38154440
[TBL] [Abstract][Full Text] [Related]
13. A selenium-containing ruthenium complex as a cancer radiosensitizer, rational design and the important role of ROS-mediated signalling.
Deng Z; Yu L; Cao W; Zheng W; Chen T
Chem Commun (Camb); 2015 Feb; 51(13):2637-40. PubMed ID: 25574525
[TBL] [Abstract][Full Text] [Related]
14. RGD-conjugated gold nanorods induce radiosensitization in melanoma cancer cells by downregulating α(v)β₃ expression.
Xu W; Luo T; Li P; Zhou C; Cui D; Pang B; Ren Q; Fu S
Int J Nanomedicine; 2012; 7():915-24. PubMed ID: 22412298
[TBL] [Abstract][Full Text] [Related]
15. RGD peptide-modified fluorescent gold nanoclusters as highly efficient tumor-targeted radiotherapy sensitizers.
Liang G; Jin X; Zhang S; Xing D
Biomaterials; 2017 Nov; 144():95-104. PubMed ID: 28834765
[TBL] [Abstract][Full Text] [Related]
16. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells.
Shan D; Li J; Cai P; Prasad P; Liu F; Rauth AM; Wu XY
Drug Deliv Transl Res; 2015 Feb; 5(1):15-26. PubMed ID: 25787336
[TBL] [Abstract][Full Text] [Related]
17. Walsuronoid B induces mitochondrial and lysosomal dysfunction leading to apoptotic rather than autophagic cell death via ROS/p53 signaling pathways in liver cancer.
Geng YD; Zhang C; Lei JL; Yu P; Xia YZ; Zhang H; Yang L; Kong LY
Biochem Pharmacol; 2017 Oct; 142():71-86. PubMed ID: 28673807
[TBL] [Abstract][Full Text] [Related]
18. SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
Zhao P; Chen L; Li LH; Wei ZF; Tong B; Jia YG; Kong LY; Xia YF; Dai Y
BMC Cancer; 2014 Dec; 14():987. PubMed ID: 25527123
[TBL] [Abstract][Full Text] [Related]
19. Selenium-driven enhancement of synergistic cancer chemo-/radiotherapy by targeting nanotherapeutics.
Liu X; Yuan Z; Tang Z; Chen Q; Huang J; He L; Chen T
Biomater Sci; 2021 Jul; 9(13):4691-4700. PubMed ID: 34019044
[TBL] [Abstract][Full Text] [Related]
20. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
